Semintra

AuthorisedVeterinary

Details

EMA number

EMEA/V/C/002436

EMA page

Therapeutic indication

Not specified

Active substances

telmisartan

🇺🇸 Also approved in the US (FDA)

TELMISARTAN AND HYDROCHLOROTHIAZIDE — ALEMBIC, approved 2023-09-12 (ANDA203010).

Most reported adverse events (US / FAERS)

17,594 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

1,497

nausea

1,426

drug ineffective

1,321

diarrhoea

1,277

🇺🇸 Also approved in the US (FDA)

TELMISARTAN AND HYDROCHLOROTHIAZIDE — ALEMBIC, approved 2023-09-12 (ANDA203010).

Most reported adverse events (US / FAERS)

17,594 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

fatigue

1,497

nausea

1,426

drug ineffective

1,321

diarrhoea

1,277

headache

1,259

dyspnoea

1,223

fall

1,169

off label use

1,141

dizziness

1,105

arthralgia

1,084

blood pressure increased

1,065

vomiting

1,033

asthenia

1,029

malaise

1,003

hypertension

962